Should statins be a part of the sepsis treatment regimen? Not yet, suggest Terblanche and colleagues [1] in the previous issue of Critical Care. Pleiotropic eff ects beyond cholesterol reduction have been reported in statins [2] [3] [4] [5] . Th ese anti-infl ammatory and immuno modu latory eff ects, seen in models of sepsis and acute lung injury (ALI), provide the basis for statin therapy in critically ill patients [6] [7] [8] [9] [10] . Observational data regarding the potential benefi cial pleiotropic eff ects of statins in sepsis and ALI have been presented, and fi ndings variously support and refute the benefi cial eff ects of statins in the infected patient. While meta-analysis suggests a potential benefi t, the few prospective random ized trials that have been published have confl ict ing conclusions [11] [12] [13] .
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Th e retrospective study by Terblanche and colleagues [1] , who followed mechanically ventilated patients without signifi cant non-pulmonary end-organ disease over their intensive care unit (ICU) stay, adds to the contro versy. Patients receiving statins had higher APACHE II (Acute Physiology and Chronic Health Evaluation II) scores (20.3 versus 17.8; P <0.0001) and were older (67.4 versus 55.5 years; P <0.0001). Th ose receiving statins also had more severe respiratory SOFA (Sepsis-related Organ Failure Assessment) scores and were more likely to have some degree of renal and cardiovascular dysfunction at baseline. Statin adminis tration was not associated with reduced incidence of non-pulmonary acute organ failure or mortality but was associated with longer ICU and hospital stays. A greater proportion of the statin group had alanine amino transferase (ALT) values of greater than three times the upper limit of normal (ULN) (11.6% versus 4.8%; P = 0.0002). Th ese elevations were brief in longevity, and no clinical untoward eff ects were noted. It is diffi cult to understand the ramifi cations, as the median time of drug delivery was just 3 days, limiting both benefi cial eff ects and harmful ones. Th e median dose of simvastatin, the predominant statin, was just 20 mg, and only one third of patients had statins started on day 1; both circumstances potentially reduced the opportunity to prevent the progres sion of organ dysfunction.
Kruger and colleagues [14] randomly assigned patients on statins after admission for sepsis to atorvastatin 20 mg (equivalent to simvastatin 40 mg) or placebo. Patients were admitted to either acute care wards or ICUs, whereas patients in the study by Terblanche and colleagues were admitted to the ICU or were mechanically ventilated. Continuation of statin therapy was not protective with regard to sepsis or markers of infl ammation. Compared with subjects in the study by Terblanche and colleagues, subjects received more doses of study drug, and 3 out of 150 patients had an elevated ALT of greater than fi ve times the ULN. Two of the three were receiving atorvastatin. No patients had creatine kinase (CK) values exceeding 10 times the ULN. Kruger and the Australian and New Zealand Intensive Care Society (ANZICS) have just concluded a study randomly assigning ICU patients with severe sepsis to atorvastatin or placebo (ACTRN12607000028404).
Craig and colleagues [15] evaluated patients with ALI from all causes and randomly assigned 60 patients to simvastatin 80 mg/day or placebo until extubation or 14 days, whichever occurred fi rst. While this study was not powered to detect diff erences in mortality, a signifi cant reduction in SOFA scores was noted at day 14, suggesting that statin administration hastens the resolution of end-organ damage. SOFA scores fell from 10.2 to 4.2 in the statin group and from 10.4 to 8.8 in the placebo group (P = 0.01). Doses were administered 88% and 82% of days in the statin and placebo groups, respectively, and no diff erences in elevated CK, ALT, or aspartate aminotransferase (AST) values between groups were noted. Th is population had higher APACHE II scores than those in the study by Terblanche and colleagues, and mean values were 25.1 and 23.3 in the statin and placebo groups, respectively. Daniel McAuley and the Irish Critical Care Trials Group have initiated a larger randomized controlled trial that has ventilator-free days (VFDs) as the primary outcome (ISRCTN88244364).
Th e National Heart, Lung, and Blood Institute (NHLBI) ARDSNet has initiated the SAILS (Statins for Acutely Injured Lungs from Sepsis) trial (NCT00979121). In this study, subjects who have ALI and who are statin-free for 72 hours are randomly assigned to rosuvastatin 20 mg (equivalent to simvastatin 80 mg) or placebo. Th e primary outcome is mortality, and secondary outcomes include VFDs, organ failure-free days, ICU-free days, and toxicity.
Some questions regarding statin administration in patients with presumed infections and systemic infl ammatory response syndrome, sepsis, severe sepsis, or ALI remain unanswered: 1. Can statins reduce mortality? 2. Are statins eff ective in preventing or reducing severity of end-organ damage? 3. Are statins eff ective in hastening the resolution of endorgan damage? 4. If the answer to any of these questions is yes, then a. Which statin is most eff ective and safest? b. What dose is most eff ective and safest? c. Do patients have to be on maintenance statins before developing critical illness? It is time to turn away from retrospective and observational studies or meta-analysis and test the plausible rationales that have been put forth. Indeed, several randomized clinical trials have been initiated to address some of these questions in patients with sepsis or ALI.
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